{
    "clinical_study": {
        "@rank": "90566", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma"
        }, 
        "brief_title": "Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 ECOG performance status: 0-2\n        Signed study specific informed consent prior to study entry\n\n        Exclusion Criteria:\n\n        Postoperative residual or recurrent tumor Evidence of distant metastases Previous\n        irradiation for the tumor in the same location Adjuvant anti-androgenic hormonal therapy\n        High risk group (NCCN guide line)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "117", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709253", 
            "org_study_id": "NCCCTS 07-253"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1", 
                "Arm 2", 
                "Arm 3", 
                "Arm 4"
            ], 
            "description": "hypofractionation study using proton beam therapy for prostate adenocarcinoma", 
            "intervention_name": "proton beam therapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "hpofractionation study using proton beam therapy", 
        "lastchanged_date": "October 16, 2012", 
        "location": {
            "contact": {
                "email": "kwancho@ncc.re.kr", 
                "last_name": "kwan ho cho, M.D.", 
                "phone": "+82 31 920 1720"
            }, 
            "facility": {
                "address": {
                    "city": "Goyang-si", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do,", 
                    "zip": "411-769"
                }, 
                "name": "National cancer center, korea"
            }, 
            "investigator": [
                {
                    "last_name": "kang hyun lee, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Byong ho nam, ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "yeon-joo kim, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma", 
        "overall_contact": {
            "email": "kwancho@ncc.re.kr", 
            "last_name": "kwan ho cho, M.D.", 
            "phone": "+82 31 920 1720"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Center, Korea", 
            "last_name": "kwan ho cho, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate biochemical failure-free survival (BCFFS)", 
            "measure": "clinical outcomes", 
            "safety_issue": "Yes", 
            "time_frame": "up to 5years from a initial follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709253"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cancer Center, Korea", 
            "investigator_full_name": "Kwan Ho Cho", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "to evaluate acute toxicities by CTCAE version 3.0", 
                "measure": "acute toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5years from a initial follow-up"
            }, 
            {
                "description": "to evaluated late toxicities by CTCAE version 3.0", 
                "measure": "late toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5years from a initial follow-up"
            }, 
            {
                "description": "to evaluated overall survival", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5years from a initial follow-up"
            }
        ], 
        "source": "National Cancer Center, Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Center, Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}